ERBB2 and triple-negative breast carcinoma: Given the patient’s poor tolerance to chemotherapy and fear of the treatment, we initially recommended chemotherapy but ultimately opted for T-DXd as a first-line drug to address HER2-low-expressing triple-negative breast cancer.